| The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY … PA Reilly, T Lehr, S Haertter, SJ Connolly, S Yusuf, JW Eikelboom, ... Journal of the American College of Cardiology 63 (4), 321-328, 2014 | 996 | 2014 |
| Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study P Bogomolov, A Alexandrov, N Voronkova, M Macievich, K Kokina, ... Journal of hepatology 65 (3), 490-498, 2016 | 452 | 2016 |
| Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial KH Liesenfeld, T Lehr, C Dansirikul, PA Reilly, SJ Connolly, ... Journal of Thrombosis and Haemostasis 9 (11), 2168-2175, 2011 | 385 | 2011 |
| Genetic determinants of dabigatran plasma levels and their relation to bleeding G Paré, N Eriksson, T Lehr, S Connolly, J Eikelboom, MD Ezekowitz, ... Circulation 127 (13), 1404-1412, 2013 | 345 | 2013 |
| Effective elimination of dabigatran by haemodialysis D Khadzhynov, F Wagner, S Formella, E Wiegert, V Moschetti, T Slowinski, ... Thrombosis and haemostasis 109 (04), 596-605, 2013 | 256 | 2013 |
| A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral … F Van de Werf, M Brueckmann, SJ Connolly, J Friedman, CB Granger, ... American heart journal 163 (6), 931-937. e1, 2012 | 243 | 2012 |
| First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B A Blank, C Markert, N Hohmann, A Carls, G Mikus, T Lehr, A Alexandrov, ... Journal of hepatology 65 (3), 483-489, 2016 | 235 | 2016 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 219 | 2023 |
| PBPK models for CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin N Hanke, S Frechen, D Moj, H Britz, T Eissing, T Wendl, T Lehr CPT: pharmacometrics & systems pharmacology 7 (10), 647-659, 2018 | 137 | 2018 |
| Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation T Lehr, S Haertter, KH Liesenfeld, A Staab, A Clemens, PA Reilly, ... The Journal of Clinical Pharmacology 52 (9), 1373-1378, 2012 | 118 | 2012 |
| Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer LS Schneider, K Von Schwarzenberg, T Lehr, M Ulrich, ... Cancer research 75 (14), 2863-2874, 2015 | 84 | 2015 |
| Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ... CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019 | 83 | 2019 |
| Targeting cyclin dependent kinase 5 in hepatocellular carcinoma–A novel therapeutic approach SM Ehrlich, J Liebl, MA Ardelt, T Lehr, EN De Toni, D Mayr, L Brandl, ... Journal of hepatology 63 (1), 102-113, 2015 | 82 | 2015 |
| Population nutrikinetics of green tea extract C Scholl, A Lepper, T Lehr, N Hanke, KL Schneider, J Brockmöller, ... PLoS One 13 (2), e0193074, 2018 | 72 | 2018 |
| Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically‐based pharmacokinetic modeling JG Wojtyniak, H Britz, D Selzer, M Schwab, T Lehr CPT: Pharmacometrics & Systems Pharmacology 9 (6), 322-331, 2020 | 71 | 2020 |
| How to disentangle psychobiological stress reactivity and recovery: A comparison of model-based and non-compartmental analyses of cortisol concentrations R Miller, JG Wojtyniak, LJ Weckesser, NC Alexander, V Engert, T Lehr Psychoneuroendocrinology 90, 194-210, 2018 | 66 | 2018 |
| Pharmacometric characterization of dabigatran hemodialysis KH Liesenfeld, A Staab, S Härtter, S Formella, A Clemens, T Lehr Clinical pharmacokinetics 52, 453-462, 2013 | 58 | 2013 |
| Biosimulation in clinical drug development T Lehr, A Staab, HG Schäfer Biosimulation in drug development, 447-483, 2008 | 58* | 2008 |
| Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification A Clemens, S Haertter, J Friedman, M Brueckmann, J Stangier, J van Ryn, ... Current medical research and opinion 28 (2), 195-201, 2012 | 54 | 2012 |
| Inhibition of cyclin‐dependent kinase 5: a strategy to improve sorafenib response in hepatocellular carcinoma therapy MA Ardelt, T Fröhlich, E Martini, M Müller, V Kanitz, C Atzberger, ... Hepatology 69 (1), 376-393, 2019 | 53 | 2019 |
